Recent investigations have begun to elucidate FOXC2’s role in cancer progression, with studies demonstrating its involvement in promoting EMT, vasculogenic mimicry, and resistance to anti-angiogenic therapy in triple-negative breast cancer29,30. The gene discussed is FOXC2; the disease is cancer.